MB-CART19.1 in Patients With R/R ALL

Adoptive Therapy With MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia

NCT03321123•Shanghai Children's Medical Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory

Interventions

MB-CART19.1

Key Dates

Start Date

December 1, 2017

Primary Completion Date

July 1, 2019

Completion Date

December 31, 2019

Last Updated

October 25, 2017

Contacts

Jing Chen, MD, PhD

CONTACT

86 18930830632 chenjing@scmc.com.cn

Benshang Li, MD, PhD

CONTACT

86 18101893712 libenshang@scmc.com.cn

Sponsors

Lead Sponsor

Shanghai Children's Medical Center

Collaborators

Miltenyi Biomedicine GmbH

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 25, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions